Bluebird moves ahead with gene therapy despite NIH recommendation; China's biotech sector comes of age;

@FierceBiotech: ICYMI: Sanofi and Regeneron's would-be blockbuster clears FDA hurdle, but questions remain. Article | Follow @FierceBiotech

@JohnCFierce: Melinta grabs $67M in pursuit of a big PhIII antibiotics finish, NDA. News | Follow @JohnCFierce

@DamianFierce: This seems to be driving the PCSK9 panelists insane. Item | Follow @DamianFierce

> Bluebird bio ($BLUE) is pressing on with plans for a new pediatric study of its gene therapy for a rare blood disorder despite the recommendation of an NIH committee, which suggested the company wait a year or two before proceeding. More

> China's push to catch up with other nations in biotech R&D is bearing fruit, Reuters reports. Story

> Israel's Intec Pharma is looking to raise $46 million in a U.S. IPO to support its development of a novel drug delivery technology. Filing

Medical Device News

@FierceMedDev: ICYMI yesterday: HeartWare tells patients how to safely use its blood pump in attempt to overcome slew of recent recalls. Article | Follow @FierceMedDev

@VarunSaxena2: India's Cipla gets first FDA approval of oral pellet to treat HIV/AIDS in infants. FierceDrugDelivery article | Follow @VarunSaxena2

> Biotronik's vascular stent determined effective in challenging cases of peripheral artery disease. Story

> KKR-backed Panasonic Healthcare to buy Bayer diabetes device biz for almost $1.2B. Article

Pharma News

@FiercePharma: GSK, Sanofi hauled up by India's competition watchdog on vaccine tenders. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Mylan recalls more injected cancer drugs it made for Pfizer at its Agila plants in India. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Does brand + generic really add up? Sandoz, Actavis execs count the ways. Article | Follow @CarlyHFierce

> Inflectra vs. Remicade study could be just what the doctor ordered for biosimilars. More

> Novartis closes in on lucrative new Cosentyx use with ankylosing spondylitis results. Story

> You're free to speak, FDA tells Amarin in bid to deflate free-speech suit. Article

Pharma Marketing News

> Merck KGaA's amped-up consumer pitch delivers much-needed sales hike. Story

> Pharma needs some 'marriage counseling' for patient relationships: report. More

> Merck's best hep C strategy is niche marketing, game theory expert figures. Story

> Want new patient relationships? Digital-savvy KOLs could be your intro. Article

> Why sue, FDA asks Amarin: You can spread the word on Vascepa already. Item

Biotech Research News

> CRISPR-Cas9 furor highlights explosive growth of gene editing in China. Report

> Do U.S. biomedical researchers really waste about $28B a year? Story

> Enzyme in mice linked to obesity, diabetes. Item

> NYU study: Blocking receptor protein CXCR4 'decimated' leukemia cells. More

> ALS researchers at Gladstone, Michigan shed new light on a key drug target. Article

Diagnostics News

> Study identifies 16 new genetic variants of Bloom syndrome. News

> U.K. researchers say earlier diagnoses of bladder cancer needed, especially among women. Report

> Health Diagnostic Laboratory rails against physician kickback claims. Story

> Roche receives FDA clearance for test to diagnose herpes using its cobas system. Article

> Exact Sciences joins forces with MD Anderson for lung cancer Dx development. More

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.